We thus selected three mutations from different loci strongly associated with three different diseases: breast cancer (the third Ashkenazi founder mutation: BRCA2 6174delT, rs80359550), the often undiagnosed iron disorder hemochromatosis (HFE C282Y, rs1800562) (Pilling et al., 2019), and cystic fibrosis (CFTR ΔF508, rs113993960); and evaluated SNIPR performance using human genomic samples of heterozygous and homozygous carriers from the Coriell repository (Figure 5A). This evidence concerns the gene BRCA2 and breast cancer.